Literature DB >> 3606662

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani.

S L Croft, R A Neal, W Pendergast, J H Chan.   

Abstract

Several alkyl phosphorylcholines and related derivatives were tested against Leishmania donovani amastigotes in mouse peritoneal macrophages in vitro and ED50 values were determined in the range of 1-12 microM. The three alkyl phosphorylcholines tested against L. donovani in BALB/c mice were active, an ED50 of 12.8 mg/kg/day X 5 was ascertained for one compound, but an alkyl phosphorylethanolamine was inactive.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3606662     DOI： 10.1016/0006-2952(87)90543-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  39 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.

Authors:  Richard D. Pearson
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

5.  Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells.

Authors:  S Reynolds; H Cederberg; S Chakrabarty
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

Authors:  Utpal Kant Singh; Rajniti Prasad; O P Mishra; B P Jayswal
Journal:  Indian J Pediatr       Date:  2006-12       Impact factor: 1.967

7.  CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.

Authors:  Suman Gupta; Shraddha A Sane; Nishi Shakya; Preeti Vishwakarma; W Haq
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

8.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

9.  Treatment of visceral leishmaniasis.

Authors:  E M Moore; D N Lockwood
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.

Authors:  R J Baumann; P P McCann; A J Bitonti
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.